Mark Fleury is a policy principal for the American Cancer Society Cancer Action Network (ACS CAN). He specializes in research, drug development, and regulatory policies along with other science and technology-related projects. He has worked extensively on reform of diagnostic testing oversight, helped lead a coalition in 2016 that authored a landscape report on drug development challenges in pediatric cancer, and led another coalition in 2017 that created a report and recommendations focused on overcoming cancer clinical trial enrollment barriers.
He currently sits on the steering committee of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, which examines the use of targeted anticancer agents used off-label in clinical settings. In addition to his ACS CAN experience, Mark’s policy work includes time as a Capitol Hill legislative advisor focusing on healthcare reform, and work at the American Association for Cancer Research (AACR). He holds a PhD in bioengineering from the Ecole Polytechnique Federale de Lausanne in Switzerland, and his former research includes investigating the mechanisms of tumor metastasis and the signaling pathways responsible for the activation of immune cells.